海泰新光汪方华：光学技术为基 医疗赛道纵深拓展

Core Viewpoint - Chinese manufacturing companies, particularly those focused on exports, are actively adjusting their global production capacity to maintain competitiveness and explore new opportunities amid the evolving Sino-U.S. trade environment [1]. Group 1: Company Strategy - Haitai New Light (688677.SH) is focusing on international capacity arrangements to address tariff challenges and is extending its development strategy into the medical device sector centered around optical technology [1][3]. - The company began considering global supply chain restructuring in 2019 due to U.S. tariffs but did not immediately establish overseas factories due to its limited scale at that time [1][3]. - In June 2023, the company initiated the construction of a production base in Thailand and established a small-scale production base in the U.S. to mitigate the impact of tariffs, which could reach up to 100% on certain products [3]. Group 2: Financial Adjustments - Starting July 2023, the company adjusted its supply chain process by changing the shipping method from direct shipments from Qingdao to U.S. customers to shipments to its U.S. subsidiary, thus internalizing tariff costs [3]. - The company negotiated a price increase of 15% to 20% with customers to cover additional costs incurred from tariffs [3]. Group 3: Market Position and Growth - The Thai production base is designed to comply with local value-added requirements, allowing the company to benefit from reduced tariffs on exports to the U.S. [3]. - Despite a transitional tariff of 10% in Thailand, the company expects to maintain its cost and profit margins, potentially increasing profits as production scales up [3]. - Haitai New Light's revenue from the U.S. market accounts for 60% to 70% of its total income, with expectations for further growth in export ratios over the next three to five years [4]. Group 4: Product Focus and Future Investments - The company is primarily focused on laparoscopic surgical products and is extending its product line into medical analysis and testing [4]. - Haitai New Light maintains a profit-centered operational strategy, with a gross margin of approximately 65% and a net margin of up to 30% in its medical segment [4]. - Future investments will focus on both optical and medical sectors, with an emphasis on a complete product mix and solid distribution channels, while also exploring AI applications in medical products [4].